SCHEMBL4780930

SCHEMBL4780930

Cc1nc2c(C(=O)NCC3CCCO3)cnn2c(C)c1Cc1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.64
TP53 P04637 6/20 0.64
KDM4E B2RXH2 9/20 0.62
ALDH1A1 P00352 9/20 0.62
HPGD P15428 7/20 0.62
NPSR1 Q6W5P4 4/20 0.62
RUVBL1 Q9Y265 1/20 0.53
HTT P42858 4/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 4/20 0.51
TSHR P16473 4/20 0.51
CASP1 P29466 3/20 0.51
CASP7 P55210 3/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4940751 0.93 HSD17B10 (0.60) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4725736 0.91 LMNA (0.62) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4939020 0.90 ALDH1A1 (0.62) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4795515 0.87 KDM4E (0.65) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4940985 0.87 ALDH1A1 (0.64) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4779873 0.85 KDM4E (0.64) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4725441 0.85 KDM4E (0.62) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4777718 0.85 ALDH1A1 (0.54) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4795734 0.85 TP53 (0.67) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL15274737 0.84 TP53 (0.52) LMNATP53KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US claimed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO claimed
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US disclosed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221129-A1 New compounds SCD, SCD5, FASN LMNA 2075/4885TP53 1572/4885KDM4E 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.